Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Anti-Tumor Activity of GDC-0077 for PIK3CA-Mutant Breast Cancer

12/12/2019

Recent News

News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
An ESMO Clinical Practice...
08/19/2026
Oncology
News
Datopotamab Deruxtecan Delays Quality-of-Life Deterioration Compared With Chemotherapy in HR-Positive, HER2-Negative Breast Cancer
08/19/2026
Emily Estrada
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and...
08/19/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Intismeran Plus Pembrolizumab Outperforms Pembrolizumab Alone in Resected Stage IIB-IV Melanoma
08/19/2026
Stephanie Holland
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3...
08/19/2026
Oncology
News
Rucaparib Plus Nivolumab Shows Biomarker-Linked Activity in Advanced Biliary Tract Cancer
08/19/2026
Emily Estrada
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02...
08/19/2026
Oncology
News
Tisagenlecleucel Shows Durable Five-Year Remissions in Pediatric and Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
08/19/2026
Emily Estrada
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase...
08/19/2026
Oncology
News
Third-Generation Anti-CD30 CAR T-Cell Therapy Shows Durable Responses in Relapsed or Refractory CD30-Positive Lymphoma
08/18/2026
Emily Estrada
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial...
08/18/2026
Oncology
News
Spartalizumab Triplet Extends Overall Survival in BRAF V600–Mutant Advanced Melanoma
08/18/2026
Stephanie Holland
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3...
08/18/2026
Oncology
News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Outperforms Cisplatin Plus Gemcitabine in Muscle-Invasive Bladder Cancer
08/12/2026
Stephanie Holland
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3...
08/12/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use